Repository logo
 
Publication

Chronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)

2020Journal article Open access
Simple item page
dc.contributor.authorMiranda, AC
dc.contributor.authorMendez, J
dc.contributor.authorSerrão, R
dc.contributor.authorVale, F
dc.contributor.authorManata, MJ
dc.contributor.authorPinto, S
dc.contributor.authorGomes, A
dc.contributor.authorValente, C
dc.contributor.authorPacheco, P
dc.contributor.authorPazos, R
dc.contributor.authorPereira, R
dc.contributor.authorMartins, A
dc.contributor.authorGermano, I
dc.contributor.authorRocha, S
dc.contributor.authorReis, AP
dc.contributor.authorSarmento-Castro, R
dc.date.accessioned2022-04-22T15:02:24Z
dc.date.available2022-04-22T15:02:24Z
dc.date.issued2020
dc.description.abstractDirect-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis C therapy, significantly improving treatment response rates, patient life expectancy and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV) were fully reimbursed by the National Health System since early 2015 and generalized use of interferon-free DAA based regimens became current practice. During 2016, the remaining DAAs were sequentially added and covered by the same health access policy. The Portuguese Study Group of Hepatitis and HIV Co-infection (GEPCOI) collected data from 15 clinical centres in Portugal, pertaining to the HCV treatment experience with DAA regimens. A cohort of 2133 patients was analysed, representing one of the largest DAA treated HCV/HIV co-infected individuals. The global sustained virologic response (SVR) achieved was 95% in this real-life cohort setting. Linear regression analysis showed significant differences in treatment response rates when using SOF plus ribavirin (RBV) combination in genotype 2 or 3 infected individuals (P < .002) and in those with liver cirrhosis (P < .002). These findings corroborate that early treatment is mandatory in HIV/HCV co-infected patients, as response rates may be negatively influenced by higher fibrosis stages and suboptimal DAA regimens. The current national Portuguese health policy should continue to promote wider treatment access and individualized therapy strategies, aiming at the elimination of HCV infection in this high-risk co-infected population.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Viral Hepat. 2020 Jul;27(7):715-720.pt_PT
dc.identifier.doi10.1111/jvh.13281.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4046
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.subjectHCC INFpt_PT
dc.subjectAdultpt_PT
dc.subjectAgedpt_PT
dc.subjectFemalept_PT
dc.subjectAntiviral Agents* / therapeutic usept_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectCoinfection* / drug therapypt_PT
dc.subjectDrug Therapy, Combinationpt_PT
dc.subjectGenotypept_PT
dc.subjectHIV Infections* / drug therapypt_PT
dc.subjectHepaciviruspt_PT
dc.subjectHepatitis C, Chronic* / drug therapypt_PT
dc.subjectHumanspt_PT
dc.subjectNigeriapt_PT
dc.subjectPortugalpt_PT
dc.subjectQuality of Lifept_PT
dc.subjectYoung Adultpt_PT
dc.subjectSofosbuvir / therapeutic usept_PT
dc.subjectTreatment Outcomept_PT
dc.titleChronic Hepatitis C Treatment in HIV Co-Infection in Portugal: Results from a Cohort OF 2133 Patients Presented by GEPCOI (Portuguese Coinfection Study Group)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage720pt_PT
oaire.citation.startPage715pt_PT
oaire.citation.titleJournal of Viral Hepatitispt_PT
oaire.citation.volume27pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Viral Hepat 2020 715.pdf
Size:
388.1 KB
Format:
Adobe Portable Document Format
Download

Collections

INF - Artigos